COVID-19 COVID-19 Vaccine FDA Pharmaceutical Industry 
HIT Consultant
AUGUST 18, 2021
The pandemic has given rise to new norms in drug development that will influence the future of the industry as we know it. The world has been in urgent need of COVID-19 vaccines, treatments, and diagnostic tools. Here’s a look at what we’ve learned from COVID-19 era regulatory practices in clinical development.
HIT Consultant
MAY 2, 2022
The FDA is attempting to address this, having issued guidelines related to diversity in clinical trials in November 2020 – perhaps prompted by widespread media coverage of the fact that the black members of the society and other people of color were underrepresented in clinical trials for COVID-19 vaccines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
SEPTEMBER 28, 2023
By Nikhil Chaudhry and Reshma Ramachandran Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. pharmaceutical market.
Hall Render
FEBRUARY 18, 2022
CMS may now enforce its COVID-19 vaccination policy for healthcare workers in all 50 states. CMS responds to states seeking vaccination mandate waivers. Federal vaccination mandate begins for healthcare workers in 24 states. HHS seeks $30B to combat COVID-19. Million in Covid Relief.
Dot Compliance
FEBRUARY 1, 2022
The global pharmaceutical industry has seen its share of challenges in recent years, from manufacturing and supply chain bottlenecks to growing demand for faster delivery of drugs to the marketplace. The next evolution is for companies to implement Industry 4.0 What will the near future bring to the table? References.
Expert insights. Personalized for you.
52 
Let's personalize your content